TENX

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Wall Street analysts forecast TENX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TENX is 25.00 USD with a low forecast of 20.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tenax Therapeutics Inc revenue for the last quarter amounts to -16.81M USD, increased 263.85 % YoY.

Tenax Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

Tenax Therapeutics Inc (TENX) has 4 emplpoyees as of December 15 2025.

Today TENX has the market capitalization of 64.75M USD.